InMed’s CEO, Eric A. Adams, presents at the Life Sciences Virtual Investor Forum on December 11, 2025. He gives a company update and presents InMed’s INM-901 Alzheimer’s disease program, sharing the promising preclinical data completed so far.
INM-901 is being developed as a potential multi-factorial treatment with preclinical data demonstrating a significant reduction in inflammatory markers associated with Alzheimer’s disease, neuroprotective effects and the ability to extend the length of neurites (neuritogenesis), signifying improved neuronal function.
Watch the presentation here at the Life Sciences Virtual Investor Forum website.